Literature DB >> 26677940

Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection.

Soren T Hoff1, Jonathan G Peter2, Grant Theron2, Mellissa Pascoe2, Pernille N Tingskov3, Henrik Aggerbeck3, Daniel Kolbus3, Morten Ruhwald1, Peter Andersen4, Keertan Dheda5.   

Abstract

C-Tb, a novel Mycobacterium tuberculosis and 6-kDa early secretory antigenic target/10-kDa culture filtrate protein (ESAT-6/CFP-10)-specific skin test, has high specificity in bacille Calmette-Guerin-vaccinated healthy controls. However, the sensitivity of C-Tb has hitherto not been determined. The objective was to determine the sensitivity of C-Tb in patients with active tuberculosis (TB) in comparison with the tuberculin skin test (TST) and QuantiFERON-TB Gold In-Tube (QFT-GIT).C-Tb and TST were randomly administered in a double-blinded fashion to one or the other forearm in 253 patients with active TB with or without HIV co-infection. QFT-GIT testing was performed prior to skin testing.Using a receiver operating characteristic curve-derived cut-point of 5 mm, C-Tb sensitivity was similar to QFT-GIT (73.9 (95% CI 67.8-79.3) versus 75.1 (95% CI 69.3-80.2)), and similar in HIV-infected and HIV-uninfected patients (76.7 (95% CI 69.0-83.3) versus 69.5 (95% CI 59.2-78.5)). However, sensitivity was significantly diminished in HIV-infected patients with CD4 counts <100 cells·mm(-3). C-Tb and QFT-GIT combined had significantly higher sensitivity than C-Tb alone (p<0.0001). C-Tb was safe with no significant adverse events. The 5 mm cut-point corresponded to that found in the previously published specificity study (TESEC-04).C-Tb has similar sensitivity compared with QFT-GIT for the diagnosis of M. tuberculosis infection. Sensitivity was reduced only in HIV-infected patients with severe immunosuppression. Further studies in different settings are required to validate the proposed 5 mm cut-point.
Copyright ©ERS 2016.

Entities:  

Mesh:

Year:  2015        PMID: 26677940     DOI: 10.1183/13993003.01464-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  13 in total

1.  Latent tuberculosis infection: An overview.

Authors:  S Kiazyk; T B Ball
Journal:  Can Commun Dis Rep       Date:  2017-03-02

Review 2.  Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection.

Authors:  Paul K Drain; Kristina L Bajema; David Dowdy; Keertan Dheda; Kogieleum Naidoo; Samuel G Schumacher; Shuyi Ma; Erin Meermeier; David M Lewinsohn; David R Sherman
Journal:  Clin Microbiol Rev       Date:  2018-07-18       Impact factor: 26.132

3.  New Genome-Wide Algorithm Identifies Novel In-Vivo Expressed Mycobacterium Tuberculosis Antigens Inducing Human T-Cell Responses with Classical and Unconventional Cytokine Profiles.

Authors:  Mariateresa Coppola; Krista E van Meijgaarden; Kees L M C Franken; Susanna Commandeur; Gregory Dolganov; Igor Kramnik; Gary K Schoolnik; Inaki Comas; Ole Lund; Corine Prins; Susan J F van den Eeden; Gro E Korsvold; Fredrik Oftung; Annemieke Geluk; Tom H M Ottenhoff
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

4.  Challenges in the Estimation of the Annual Risk of Mycobacterium tuberculosis Infection in Children Aged Less Than 5 Years.

Authors:  P Y Khan; Judith R Glynn; T Mzembe; D Mulawa; R Chiumya; Amelia C Crampin; Katharina Kranzer; Katherine L Fielding
Journal:  Am J Epidemiol       Date:  2017-10-15       Impact factor: 4.897

5.  Antigens Rv0310c and Rv1255c are promising novel biomarkers for the diagnosis of Mycobacterium tuberculosis infection.

Authors:  Liulin Luo; Lin Zhu; Jun Yue; Jianping Liu; Guoyuan Liu; Xuelian Zhang; Honghai Wang; Ying Xu
Journal:  Emerg Microbes Infect       Date:  2017-07-12       Impact factor: 7.163

6.  Evaluation of Rv0220, Rv2958c, Rv2994 and Rv3347c of Mycobacterium tuberculosis for serodiagnosis of tuberculosis.

Authors:  Xiaolong You; Ranhui Li; Kanglin Wan; Liangzhuan Liu; Xiaoping Xie; Lanhua Zhao; Ning Wu; Xiangying Deng; Li Wang; Yanhua Zeng
Journal:  Microb Biotechnol       Date:  2017-02-20       Impact factor: 5.813

7.  Clinical Application of Interferon-γ Release Assays for the Prevention of Tuberculosis in Countries with Low Incidence.

Authors:  Christoph Lange; Anna M Mandalakas; Barbara Kalsdorf; Claudia M Denkinger; Martina Sester
Journal:  Pathog Immun       Date:  2016-01-04

8.  Comparative sensitivity of the test with tuberculosis recombinant allergen, containing ESAT6-CFP10 protein, and Mantoux test with 2 TU PPD-L in newly diagnosed tuberculosis children and adolescents in Moscow.

Authors:  Liudmila Slogotskaya; Elena Bogorodskaya; Diana Ivanova; Tatiana Sevostyanova
Journal:  PLoS One       Date:  2018-12-21       Impact factor: 3.240

9.  C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial.

Authors:  Henrik Aggerbeck; Morten Ruhwald; Søren T Hoff; Bettine Borregaard; Elizabeth Hellstrom; Mookho Malahleha; Mirna Siebert; Mashra Gani; Vincent Seopela; Andreas Diacon; Madeleine Lourens; Peter Andersen; Keertan Dheda
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

10.  Comparison of immunogenicity and vaccine efficacy between heat-shock proteins, HSP70 and GrpE, in the DnaK operon of Mycobacterium tuberculosis.

Authors:  Woo Sik Kim; Jong-Seok Kim; Hong Min Kim; Kee Woong Kwon; Seok-Yong Eum; Sung Jae Shin
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.